Teleflex Reports Positive Results For Its Arrow Central Venous Catheter

(RTTNews) - Teleflex Inc. (TFX) Wednesday announced a positive result for its Arrow Central Venous Catheter or CVC with ARROWg+ard Blue Technology. According to the latest published research, it can reduce both catheter-related bloodstream infections and direct costs associated with treating infections, even when the infection risk is already low.

According to the company, the antimicrobial catheter with ARROWg+ard Blue Technology outperformed an unprotected CVC in both infection reduction and total cost per patient. Within the study, the protected catheter achieved a zero infection rate of 0/1,000 catheter days.

The study focused only on CVCs inserted into the subclavian area, an insertion site associated with a low risk of CRBSI in patients admitted to the ICU. That location has been shown to be associated with lower overall infection risk, compared to the jugular and femoral infection sites. The study examined a total of 871 catheters and 6,040 catheter days.